VCM
ARCT icon

Versant Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Versant Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.72K Buy
405
+90
+29% +$709 ﹤0.01% 2527
2026
Q1 		$2.43K Buy
315
+50
+19% +$365 ﹤0.01% 2533
2025
Q4 		$1.62K Buy
265
+204
+334% +$2.2K ﹤0.01% 2468
2025
Q3 		$1.12K Hold
61
– – ﹤0.01% 2492
2025
Q2 		$794 Sell
61
-137
-69% -$1.62K ﹤0.01% 2512
2025
Q1 		$2.1K Buy
198
+142
+254% +$2.25K ﹤0.01% 2264
2024
Q4 		$950 Hold
56
– – ﹤0.01% 2207
2024
Q3 		$1.3K Buy
+56
New +$1.2K ﹤0.01% 1680

Other funds holding ARCT

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Versant Capital Management's ARCT Position: Q2 2026 in Review

Versant Capital Management increased its Arcturus Therapeutics (ARCT) stake by 29% in Q2 2026, buying an estimated $709 and bringing the position to 405 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2527.

Versant Capital Management first reported a position in ARCT in Q3 2024 and has held it in 8 quarters since. 8 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Versant Capital Management held 405 shares of Arcturus Therapeutics worth $2.72K as of Q2 2026.
  • Versant Capital Management bought 90 Arcturus Therapeutics shares in Q2 2026, an estimated $709.
  • Arcturus Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2527 holding.
  • Versant Capital Management first reported a position in Arcturus Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 8 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.